The 60-second version of Bajaj HealthCare Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹646 Cr | ₹473 Cr | ₹543 Cr | ₹611 Cr | -1.8% |
| EBITDA | ₹121 Cr | ₹82 Cr | ₹97 Cr | ₹111 Cr | -2.9% |
| EBITDA Margin | 18.8% | 17.3% | 17.8% | 18.2% | — |
| PAT (Net Profit) | ₹43 Cr | -₹84 Cr | ₹39 Cr | ₹16 Cr | -28.4% |
| EPS | ₹15.59 | ₹-30.36 | ₹13.12 | ₹4.97 | -31.7% |
| ROE | 11.7% | -30.1% | 8.5% | 3.0% | — |
| ROCE | 20.4% | 3.8% | 13.3% | 8.4% | — |
| Total Debt | ₹415 Cr | ₹333 Cr | ₹223 Cr | ₹249 Cr | -15.7% |
| Free Cash Flow | -₹116 Cr | ₹62 Cr | ₹10 Cr | ₹15 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation.